Video

Dr. Soares on the Standard of Care in Metastatic Pancreatic Cancer

Heloisa P. Soares, MD, PhD, discusses the standard of care in metastatic pancreatic cancer.

Heloisa P. Soares, MD, PhD, medical oncologist, assistant professor, Huntsman Cancer Institute, University of Utah, discusses the standard of care in metastatic pancreatic cancer.

Currently, in the treatment landscape for locally advanced metastatic pancreatic cancer, 2chemotherapy regimens are available, Soares explains. The standard options include FOLFIRINOX and gemcitabine plus nab-paclitaxel (Abraxane). No study has compared these regimens head-to-head, which makes selecting between them challenging. Moreover, FOLFIRINOX is typically reserved for patients with good ECOG performance status, Soares says.

Ultimately, gemcitabine and nab-paclitaxel are favored compared with FOLFIRINOX because the doublet is better tolerated, Soares concludes.

Related Videos
John L. Marshall, MD
Petros Grivas, MD, PhD
Noopur S. Raje, MD
Atish D. Choudhury, MD, PhD
Benjamin Levy, MD
Paolo Tarantino, MD
Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study
Sujith Samarasinghe, MD
Suzanne Trudel, MSc, MD
Consuelo Bertossi, MD